Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the ...
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...